Appendix F1— Proficiency Testing for Public Health Laboratories Providing SARS-CoV EIA and RT-PCR Diagnostics
Supplement F: Laboratory Guidance
Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) Version 2/3
CDC has developed and validated diagnostic assays for SARS-CoV, including an enzyme immunoassay (EIA) for detection of serum antibodies to SARS-CoV and a reverse transcription-polymerase chain reaction (RT-PCR) assay for detection of SARS-CoV RNA. Both the EIA and the RT-PCR tests are sensitive and highly specific for diagnosis of SARS-CoV infection. Testing with these assays is now available through state public health laboratories and CDC’s Laboratory Response Network (LRN).
CDC is in the process of developing and implementing a quality assurance program to evaluate each laboratory's testing proficiency. To demonstrate competence in performing these tests, public health and LRN laboratories will be required to successfully identify positive and negative specimens provided in the proficiency panels.
Process for Proficiency Panel Testing
- EIA proficiency panels will be shipped to designated public health laboratories, and RT-PCR proficiency panels will be distributed through the LRN.
- Each laboratory should complete testing promptly and return results by the designated date.
- Proficiency panel test results must be returned by electronic mail using a designated format.
- Each laboratory will receive a complete summary of its own results as well as an aggregate summary of performance from all laboratories completing the proficiency testing.
- CDC will provide a certificate of participation to the participating laboratory to help fulfill quality assurance requirements.
Results obtained from a laboratory’s proficiency testing will initially be considered “educational,” and laboratories will not be required to undergo additional training as remediation. However, successful completion of the proficiency test will be required for approval of a public health or LRN laboratory as a confirmatory testing site.Top of Page
- I. Rationale and Goals
- II. Lessons Learned
- III. Diagnostic Assays
- IV. CDC's Laboratory Diagnostics Plan
- Appendix F1: Proficiency Testing for Public Health Laboratories Performing SARS-CoV EIA and RT-PCR Diagnostics
- Appendix F2: SARS-CoV Specimen Testing Guidelines: RT-PCR and Serology
- Appendix F3: Guidelines for Clinicians: The Consent Process for SARS-CoV RT-PCR and EIA Testing at CDC and Public Health Laboratories
- Appendix F4: Guidelines for Collecting Specimens from Potential SARS Patients
- Appendix F5: Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with SARS-CoV
- Appendix F6: Guidelines for Medical Surveillance of Laboratory Personnel Working with SARS-CoV
- Appendix F7: Fact Sheet for Clinicians: Interpreting SARS-CoV Test Results from CDC and Other Public Health Laboratories
- Appendix F8: Guidelines for Laboratory Diagnosis of SARS-CoV Infection
- Page last reviewed: May 3, 2005
- Page last updated: May 3, 2005
- Content source: